News Releases

All Years

Search

Go

Advanced Search

SEP 19, 2023 Inhibrx Retains Rights to INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency Outside of the United States and Canada

AUG 29, 2023 Inhibrx Announces \$200 Million Private Placement Financing

AUG 7, 2023 Inhibrx Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

MAY 30, 2023 Inhibrx Granted Fast Track Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency

MAY 8, 2023 Inhibrx Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

Show 5 🗸 per page



